Posted by Michael Wonder on 25 Nov 2025
Avenzo Therapeutics granted fast track designation for AVZO-103, a potential best in class nectin4/TROP2 bispecific antibody drug conjugate, for the treatment of patients with urothelial cancer previously treated with enfortumab vedotin
24 November 2025 - Avenzo Therapeutics today announced the US FDA granted fast track designation to AVZO-103, a potential best in class Nectin4/TROP2 bispecific antibody drug conjugate.
The designation was granted for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received enfortumab vedotin. There are no approved antibody-drug conjugates for patients previously treated with enfortumab vedotin.
